Literature DB >> 30215238

First Case of Catheter-related Malassezia pachydermatis Fungemia in an Adult.

Jaehyeon Lee1,2, Yong Gon Cho3,2, Dal Sik Kim3,2, Sam Im Choi3,2, Hye Soo Lee3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30215238      PMCID: PMC6143468          DOI: 10.3343/alm.2019.39.1.99

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


× No keyword cloud information.
Dear Editor, Malassezia yeast species are normal microbiota in the skin of humans and various animals and are mainly lipophilic. Unlike other Malassezia species, M. pachydermatis is non-lipid-dependent; it is a zoonophilic yeast that has been associated with otitis externa and seborrheic dermatitis in dogs [1]. Reported Malassezia species infections have mainly involved M. furfur, and most were localized skin infections [12]. Systemic infection by M. pachydermatis in adults is extremely rare, with only three cases being reported so far (Table 1) [345]. We report a case of M. pachydermatis fungemia in an adult. The Institutional Review Board of Chonbuk National University Hospital exempted this study (IRB No. CUH 2014-08-002).
Table 1

Cases of Malassezia pachydermatis systemic infection reported in adults to date

No. CasePredisposing DiagnosisAge/SexProphylactic antifungal agentsReported risk factorsNot considered risk factors (to date)OutcomeReference
Arterial catherizationContact with a potential carrier, including animalsLipid infusionIntravascular devices
1Acute myeloid leukemia21/MNoN/MYesNoTwo central cathetersDied3 (Lautenbach et al., 1998)
2Acute myeloid leukemia69/MPosaconazoleN/MNoN/MPeripherally inserted central catheter lineImproved4 (Choudhury et al., 2014)
3Leprosy, Pneumonia53/MNoNoNoNoMidline catheterFully recovered5 (Roman et al., 2016)
Present patientGastric cancer62/MNoYesNoYesChemoportDied

Abbreviations: N/M, not mentioned; M, male.

A 62-year-old male presented to the emergency room of Chonbuk National University Hospital in May 2014 with abdominal pain. He had undergone radical total gastrectomy with adjuvant chemotherapy for poorly differentiated (stage IIIa, T2bN2M0) tubular adenocarcinoma a month previously. On arrival, he was diagnosed as having ileus and an intraabdominal abscess. On hospital day 32, his white blood cell count and C-reactive protein level increased to 1.6×109/L and 1,122.1 nmol/L, respectively, and his body temperature was 37℃. Two sets of venous blood cultures (FA Plus, FN Plus, BacT/Alert 3D system, bioMérieux, Durham, NC, USA) were conducted. Following three days of incubation, very tiny, dry-looking, creamy colonies that broke easily were observed on 5% sheep blood agar and Sabouraud dextrose agar. These colonies were identified as M. pachydermatis using Vitek 2 (bioMérieux, Hazelwood, MO, USA) and VITEK MS (bioMérieux, Marcy L'Etoile, France). Internal transcribed spacer ribosomal RNA sequencing demonstrated 100% identity with GenBank entry NR 126114. A total of four sets (FA Plus, FN Plus) of blood culture—two sets of venous blood culture and two sets of blood culture—were conducted, and all sets gave positive results. The differential time to positivity (DTP) for the chemoport and peripheral venous blood was six hours and five hours, respectively. The patient was treated with a lipid infusion one day after admission, and colony growth was enhanced with olive oil. Antifungal susceptibility results using ETEST (bioMérieux, Marcy L'Etoile, France) demonstrated that the minimal inhibitory concentrations of fluconazole, 5-flucytosine, and voriconazole were 32 µg/mL, >32 µg/mL, and 0.25 µg/mL, respectively [6]. The source of M. pachydermatis infection in this case is unclear, as the patient, his family, and the medical team confirmed that the patient had no contact with dogs. As most M. pachydermatis systemic infections are reported in neonates, risk factors have been determined for only pediatric patients [78]. There is no clear consensus concerning risk factors in adults because of the low incidence in adults (only three cases to date; Table 1) [345]. A recent study suggested that a DTP over two hrs in catheter-related candidemia, except for Candida glabrata, is an optimal cut-off [9]. Although the DTP cut-off has not been determined for Malassezia species, in this case, the DTP was over five hours. We therefore hypothesize that this is a case of catheter-related fungemia, as our patient had a chemoport. Although Chang et al. [2] identified various risk factors for Malassezia infections, they did not consider the influence of intravascular devices because their study was conducted in a neonatal intensive care unit. Lipid infusion could also be a risk factor. Standardized assays to determine the in vitro antifungal susceptibilities of Malassezia species are unavailable; therefore, we carried out antifungal susceptibility tests based on the CLSI method [6]; to date, most of the results have been reported for animal isolates. The three previously reported fungemia cases in adults were treated with amphotericin B; however, no susceptibility test results are available [345]. Although our patient was treated with amphotericin B for two days, he died of multiple organ failure. As there is no study on the DTP cut-off in Malassezia infections, and there is limited information regarding treatment, clinicians should consider an approach similar to the one outlined for C. glabrata in the European Society of Clinical Microbiology and Infectious Diseases guidelines for the diagnosis and management of Candida diseases [10]. In conclusion, although information regarding human infections is limited, lipid infusion and intravascular catheters should be considered as risk factors for M. pachydermatis infection in adults. Further studies on the risk factors and antifungal susceptibility tests are needed.
  10 in total

1.  Malassezia pachydermatis infections.

Authors:  P M Groshek
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  In vitro evaluation of Malassezia pachydermatis susceptibility to azole compounds using E-test and CLSI microdilution methods.

Authors:  Claudia Cafarchia; Luciana A Figueredo; Roberta Iatta; Valeriana Colao; Maria T Montagna; Domenico Otranto
Journal:  Med Mycol       Date:  2012-04-03       Impact factor: 4.076

4.  Malassezia pachydermatis fungaemia in an adult on posaconazole prophylaxis for acute myeloid leukaemia.

Authors:  Saugata Choudhury; Ryan Llorin Marte
Journal:  Pathology       Date:  2014-08       Impact factor: 5.306

5.  Diagnostic usefulness of differential time to positivity for catheter-related candidemia.

Authors:  Ki-Ho Park; Mi Suk Lee; Sang-Oh Lee; Sang-Ho Choi; Heungsup Sung; Mi-Na Kim; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

Review 6.  Malassezia species in healthy skin and in dermatological conditions.

Authors:  Asja Prohic; Tamara Jovovic Sadikovic; Mersiha Krupalija-Fazlic; Suada Kuskunovic-Vlahovljak
Journal:  Int J Dermatol       Date:  2015-12-29       Impact factor: 2.736

7.  An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs.

Authors:  H J Chang; H L Miller; N Watkins; M J Arduino; D A Ashford; G Midgley; S M Aguero; R Pinto-Powell; C F von Reyn; W Edwards; M M McNeil; W R Jarvis
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

Review 8.  The Malassezia genus in skin and systemic diseases.

Authors:  Georgios Gaitanis; Prokopios Magiatis; Markus Hantschke; Ioannis D Bassukas; Aristea Velegraki
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

9.  Clinical and microbiological features of infection with Malassezia pachydermatis in high-risk infants.

Authors:  P A Mickelsen; M C Viano-Paulson; D A Stevens; P S Diaz
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

10.  Malassezia pachydermatis fungemia in an adult with multibacillary leprosy.

Authors:  Jorge Roman; Prabhava Bagla; Ping Ren; Lucas S Blanton; Megan A Berman
Journal:  Med Mycol Case Rep       Date:  2016-06-02
  10 in total
  6 in total

1.  In Vitro Azole and Amphotericin B Susceptibilities of Malassezia furfur from Bloodstream Infections Using E-Test and CLSI Broth Microdilution Methods.

Authors:  Wafa Rhimi; Chioma Inyang Aneke; Adriana Mosca; Domenico Otranto; Claudia Cafarchia
Journal:  Antibiotics (Basel)       Date:  2020-06-26

2.  Galleria mellonella as a Novelty in vivo Model of Host-Pathogen Interaction for Malassezia furfur CBS 1878 and Malassezia pachydermatis CBS 1879.

Authors:  Maritza Torres; Elkin Nicolás Pinzón; Flor Maria Rey; Heydys Martinez; Claudia Marcela Parra Giraldo; Adriana Marcela Celis Ramírez
Journal:  Front Cell Infect Microbiol       Date:  2020-05-05       Impact factor: 5.293

Review 3.  Malassezia Yeasts in Veterinary Dermatology: An Updated Overview.

Authors:  Jacques Guillot; Ross Bond
Journal:  Front Cell Infect Microbiol       Date:  2020-02-28       Impact factor: 5.293

Review 4.  Use of Essential Oils in Veterinary Medicine to Combat Bacterial and Fungal Infections.

Authors:  Valentina Virginia Ebani; Francesca Mancianti
Journal:  Vet Sci       Date:  2020-11-30

Review 5.  Malassezia: Zoonotic Implications, Parallels and Differences in Colonization and Disease in Humans and Animals.

Authors:  Stefan Hobi; Claudia Cafarchia; Valentina Romano; Vanessa R Barrs
Journal:  J Fungi (Basel)       Date:  2022-07-04

Review 6.  Malassezia spp. Yeasts of Emerging Concern in Fungemia.

Authors:  Wafa Rhimi; Bart Theelen; Teun Boekhout; Domenico Otranto; Claudia Cafarchia
Journal:  Front Cell Infect Microbiol       Date:  2020-07-28       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.